Heartsring Medipharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 22-06-2024
- Paid Up Capital ₹ 0.10 M
as on 22-06-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.50 M
as on 22-06-2024
- Revenue 30.09%
(FY 2018)
- Profit 52.50%
(FY 2018)
- Ebitda 28.90%
(FY 2018)
- Net Worth 47.35%
(FY 2018)
- Total Assets -9.85%
(FY 2018)
About Heartsring Medipharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.50 M.
Sandeep Jaiswal and Manish Jaiswal serve as directors at the Company.
- CIN/LLPIN
U33111UP2011PTC043211
- Company No.
043211
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jan 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Heartsring Medipharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Jaiswal  | Director | 18-Jan-2011 | Current |
| Manish Jaiswal | Director | 18-Jan-2011 | Current |
Financial Performance of Heartsring Medipharma.
Heartsring Medipharma Private Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 30.09% increase. The company also saw a substantial improvement in profitability, with a 52.5% increase in profit. The company's net worth Soared by an impressive increase of 47.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Heartsring Medipharma?
In 2018, Heartsring Medipharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vedinova Life Sciences Private LimitedActive 1 year 9 monthsSandeep Jaiswal and Manish Jaiswal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of Patiala Creation Date: 10 Mar 2015 | ₹0.50 M | Open |
State Bank Of Patiala Creation Date: 10 Mar 2015 | ₹2.00 M | Open |
How Many Employees Work at Heartsring Medipharma?
Unlock and access historical data on people associated with Heartsring Medipharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Heartsring Medipharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Heartsring Medipharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
